Experts examine the potential role of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for ...

The PEACE-1 trial (NCT01957436) revealed that adding radiotherapy to standard of care (SOC) and abiraterone significantly ...

Panelists discuss how the CEPHEUS trial demonstrates the comparative efficacy and safety of subcutaneous daratumumab combined with VRd vs VRd alone in patients with transplant-ineligible or transplant ...

Virginia G. Kaklamani, MD, DSc, discusses findings from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year ...

Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes ...

The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...

Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

The FDA has issued a complete response letter to the biologics license application seeking the approval of tabelecleucel for ...